BACKGROUND: Among women worldwide, major depression (MDD) and heart disease rank first and second, respectively, in burden of disease. Although selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed, possible inhibition of nitric oxide (NO) function has caused concerns about their effects on protective vascular mechanisms. Our study aimed to determine the effect of SSRIs on flow-mediated vascular dilatation (FMD), platelet aggregation, and platelet NO production among women. METHODS: Women (n=28) without known cardiovascular disease were recruited prior to undergoing SSRI treatment for MDD, postpartum depression (PPD), or premenstrual dysphoric disorder (PMDD). Symptoms were quantified using the Hamilton Depression/Anxiety and Beck Depression scales. FMD, platelet aggregation, and platelet NO production were measured before and after 1 month of SSRI (sertraline, fluoxetine, or paroxetine) therapy. RESULTS: Depression and anxiety symptoms decreased significantly with SSRI treatment (ps <0.01). FMD and platelet aggregation did not differ between pre- and posttreatment, although FMD rose to the normal range (≥ 8%) in two of three women with abnormal FMD prior to SSRI treatment. We observed a 21% decrease (p=0.024) in platelet NO production. CONCLUSIONS: SSRI treatment had little effect on FMD or platelet aggregation. The health impact of decreased NO production is unclear, particularly in this relatively young group of women without cardiovascular disease, but should be considered in future studies focusing on SSRI safety in patients with cardiovascular disease.
BACKGROUND: Among women worldwide, major depression (MDD) and heart disease rank first and second, respectively, in burden of disease. Although selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed, possible inhibition of nitric oxide (NO) function has caused concerns about their effects on protective vascular mechanisms. Our study aimed to determine the effect of SSRIs on flow-mediated vascular dilatation (FMD), platelet aggregation, and platelet NO production among women. METHODS:Women (n=28) without known cardiovascular disease were recruited prior to undergoing SSRI treatment for MDD, postpartum depression (PPD), or premenstrual dysphoric disorder (PMDD). Symptoms were quantified using the Hamilton Depression/Anxiety and Beck Depression scales. FMD, platelet aggregation, and platelet NO production were measured before and after 1 month of SSRI (sertraline, fluoxetine, or paroxetine) therapy. RESULTS:Depression and anxiety symptoms decreased significantly with SSRI treatment (ps <0.01). FMD and platelet aggregation did not differ between pre- and posttreatment, although FMD rose to the normal range (≥ 8%) in two of three women with abnormal FMD prior to SSRI treatment. We observed a 21% decrease (p=0.024) in platelet NO production. CONCLUSIONS: SSRI treatment had little effect on FMD or platelet aggregation. The health impact of decreased NO production is unclear, particularly in this relatively young group of women without cardiovascular disease, but should be considered in future studies focusing on SSRI safety in patients with cardiovascular disease.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: D L Musselman; U M Marzec; A Manatunga; S Penna; A Reemsnyder; B T Knight; A Baron; S R Hanson; C B Nemeroff Journal: Arch Gen Psychiatry Date: 2000-09
Authors: Donna Jo McCloskey; Teodor T Postolache; Bernard J Vittone; Khanh L Nghiem; Jude L Monsale; Robert A Wesley; Margaret E Rick Journal: Transl Res Date: 2007-11-20 Impact factor: 7.012
Authors: Louis T van Zyl; Francois Lespérance; Nancy Frasure-Smith; Alex I Malinin; Dan Atar; Marc-André Laliberté; Victor L Serebruany Journal: J Thromb Thrombolysis Date: 2008-01-11 Impact factor: 2.300
Authors: Navein Arumugasaamy; Alana Gudelsky; Amelia Hurley-Novatny; Peter C W Kim; John P Fisher Journal: Adv Healthc Mater Date: 2019-08-13 Impact factor: 9.933
Authors: Deborah R Kim; Emily Pinheiro; James F Luther; Heather F Eng; John L Dills; Stephen R Wisniewski; Katherine L Wisner Journal: J Psychiatr Res Date: 2015-11-19 Impact factor: 4.791
Authors: Jacqueline K Limberg; Darren P Casey; Joel D Trinity; Wayne T Nicholson; D Walter Wray; Michael E Tschakovsky; Daniel J Green; Ylva Hellsten; Paul J Fadel; Michael J Joyner; Jaume Padilla Journal: Am J Physiol Heart Circ Physiol Date: 2019-12-30 Impact factor: 4.733
Authors: Shiloh Cleveland; Kristina Reed; Jordan L Thomas; Olujimi A Ajijola; Ramin Ebrahimi; Tzung Hsiai; Amit Lazarov; Amanda K Montoya; Yuval Neria; Daichi Shimbo; Kate Wolitzky-Taylor; Jennifer A Sumner Journal: BMJ Open Date: 2021-05-05 Impact factor: 2.692
Authors: Tye Dawood; David A Barton; Elisabeth A Lambert; Nina Eikelis; Gavin W Lambert Journal: Front Psychiatry Date: 2016-02-18 Impact factor: 4.157
Authors: Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes Journal: BMC Med Date: 2020-10-19 Impact factor: 8.775
Authors: Jennifer B Weggen; Ashley M Darling; Aaron S Autler; Austin C Hogwood; Kevin P Decker; Brandon Imthurn; Gina M Tuzzolo; Ryan S Garten Journal: Am J Physiol Regul Integr Comp Physiol Date: 2021-06-02 Impact factor: 3.210
Authors: Emily C Smith; Jorge Celedonio; Victor C Nwazue; Emily M Garland; Sachin Y Paranjape; Abby H Chopoorian; Amr Wahba; Italo Biaggioni; Bonnie Black; Cyndya A Shibao; André Diedrich; Luis E Okamoto; Satish R Raj; Alfredo Gamboa Journal: Clin Auton Res Date: 2021-03-10 Impact factor: 5.625